Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petra Glander

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
British Journal of Clinical Pharmacology|February 23, 2021
Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN studyClaudia Sommerer, Mercè Brunet, Klemens Budde, et al.
Therapeutic Drug Monitoring|February 17, 2007
Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humansTorsten Böhler, Jochen Nolting, Nassim Kamar, et al.
Clinical Immunology (Orlando, Fla.)|February 3, 2006
Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine AJohannes Waiser, Michael Schneider, Sara Eljazyfer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2009
Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantationNassim Kamar, Petra Glander, Jochen Nolting, et al.
Transplantation|February 24, 2007
Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomesKlemens Budde, Petra Glander, Bernhard K Krämer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 13, 2010
Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patientsPetra Glander, Claudia Sommerer, Wolfgang Arns, et al.
Pharmacogenetics and Genomics|September 7, 2010
Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulationsMarkus Wehland, Steffen Bauer, Susanne Brakemeier, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 4, 2004
Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantationPetra Glander, Pia Hambach, Kay-Patrick Braun, et al.
Therapeutic Drug Monitoring|November 14, 2018
Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant RecipientsEva Schrezenmeier, Friederike Hoffmann, Carsten Jaeger, et al.
Therapeutic Drug Monitoring|May 29, 2007
Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoringKlemens Budde, Helio Tedesco-Silva, Jose Medina Pestana, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
British Journal of Clinical Pharmacology|February 23, 2021
Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN studyClaudia Sommerer, Mercè Brunet, Klemens Budde, et al.
Therapeutic Drug Monitoring|February 17, 2007
Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humansTorsten Böhler, Jochen Nolting, Nassim Kamar, et al.
Clinical Immunology (Orlando, Fla.)|February 3, 2006
Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine AJohannes Waiser, Michael Schneider, Sara Eljazyfer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 3, 2009
Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantationNassim Kamar, Petra Glander, Jochen Nolting, et al.
Transplantation|February 24, 2007
Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomesKlemens Budde, Petra Glander, Bernhard K Krämer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 13, 2010
Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patientsPetra Glander, Claudia Sommerer, Wolfgang Arns, et al.
Pharmacogenetics and Genomics|September 7, 2010
Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulationsMarkus Wehland, Steffen Bauer, Susanne Brakemeier, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 4, 2004
Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantationPetra Glander, Pia Hambach, Kay-Patrick Braun, et al.
Therapeutic Drug Monitoring|November 14, 2018
Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant RecipientsEva Schrezenmeier, Friederike Hoffmann, Carsten Jaeger, et al.
Therapeutic Drug Monitoring|May 29, 2007
Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoringKlemens Budde, Helio Tedesco-Silva, Jose Medina Pestana, et al.
Pageof 5